Hsbc Holdings PLC Has $1.34 Million Stock Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Hsbc Holdings PLC cut its holdings in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 79.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 111,398 shares of the company's stock after selling 437,886 shares during the period. Hsbc Holdings PLC's holdings in Elanco Animal Health were worth $1,344,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. FMR LLC boosted its position in shares of Elanco Animal Health by 1,153.6% in the fourth quarter. FMR LLC now owns 40,232,327 shares of the company's stock valued at $487,213,000 after acquiring an additional 37,022,891 shares during the period. Norges Bank purchased a new position in shares of Elanco Animal Health during the 4th quarter valued at about $47,424,000. Brandes Investment Partners LP lifted its holdings in shares of Elanco Animal Health by 66.9% in the 4th quarter. Brandes Investment Partners LP now owns 5,731,180 shares of the company's stock worth $69,405,000 after acquiring an additional 2,296,691 shares during the last quarter. Magnetar Financial LLC grew its stake in shares of Elanco Animal Health by 13.7% during the fourth quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock valued at $145,711,000 after buying an additional 1,454,082 shares during the last quarter. Finally, Prudential Financial Inc. lifted its position in Elanco Animal Health by 40.4% in the fourth quarter. Prudential Financial Inc. now owns 4,224,997 shares of the company's stock valued at $51,165,000 after purchasing an additional 1,214,992 shares during the last quarter. 97.48% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Elanco Animal Health

In other news, Director Lawrence Erik Kurzius bought 10,000 shares of the company's stock in a transaction dated Tuesday, March 11th. The shares were acquired at an average cost of $10.20 per share, with a total value of $102,000.00. Following the completion of the transaction, the director now directly owns 111,459 shares in the company, valued at approximately $1,136,881.80. The trade was a 9.86 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.89% of the company's stock.

Analyst Ratings Changes

ELAN has been the topic of several recent research reports. Barclays reduced their price target on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, February 26th. UBS Group reduced their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a report on Wednesday, February 26th. Piper Sandler decreased their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Morgan Stanley dropped their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus cut their target price on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a research report on Monday, April 14th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Hold" and an average price target of $14.67.

Elanco Animal Health Stock Performance

ELAN traded down $0.12 during trading on Monday, reaching $9.63. The company's stock had a trading volume of 4,374,028 shares, compared to its average volume of 4,946,557. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company's fifty day moving average price is $9.86 and its 200-day moving average price is $11.45. Elanco Animal Health Incorporated has a 52-week low of $8.02 and a 52-week high of $18.80. The company has a market capitalization of $4.78 billion, a price-to-earnings ratio of 24.08, a price-to-earnings-growth ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The firm had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the firm earned $0.08 EPS. The business's quarterly revenue was down 1.4% on a year-over-year basis. On average, equities analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.